Glenmark gets USFDA nod for generic drug with 180-day exclusivity

The USFDA noted that the Mumbai-based drug firm was the first abbreviated new drug application (ANDA) applicant with a paragraph IV certification for Calcipotriene and Betamethasone Dipropionate Foam, it added. "Therefore, with this approval, Glenmark is eligible for 180 days of generic drug exclusivity for Calcipotriene and Betamethasone Dipropionate Foam," the drug firm said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8ZMSYO9
via IFTTT